Citius Pharma Q2 net loss $11.5M; cash only $26K; needs capital beyond May 2025

Citius Pharmaceuticals, Inc.

2025-Q2 EPS reported -$2.58 vs consensus -$0.60 ▼ miss (-328.7%)

Net loss of $11.5M ($1.27 per share) for Q2 fiscal 2025 vs $8.5M a year ago.
Cash and cash equivalents only $26,410 as of March 31, 2025.
Company will need additional capital to support operations beyond May 2025.
R&D expenses $3.8M; G&A expenses $4.8M, both up vs prior year.
Plans to secure financing for LYMPHIR launch; retained Jefferies for strategic alternatives.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.